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Abstract
Introduction: The aim was to evaluate the risk of acute side effects in the lung
after 3-dimensional conformal radiotherapy (3D-CRT) in patients treated for non-
small cell lung cancer (NSCLC). An attempt was made to single out clinical factors
and factors related to treatment technique which may induce acute post-
radiation pneumonitis.
Material and methods: The analysis concerned 34 consecutive patients who
underwent radical radiation therapy for NSCLC. Intensity of early toxicity was
evaluated using modified RTOG/EORTC toxicity score. The endpoint for this
analysis was the occurrence of radiation pneumonitis of grade 2 or higher.
Factors related to treatment techniques were included in the statistical analysis. 
Results: Fifty-three percent of patients included in the study suffered from acute
post-radiation pneumonitis. The results of the study revealed the existence of
lung tissue sensitivity to low doses of ionizing radiation. The multivariate analysis
showed that total lung volume receiving a low dose of 10 Gy increased the risk
of post-radiation pneumonitis (p = 0.01). 
Conclusions: Acute post-radiation pneumonitis was a relevant clinical problem
in patients who underwent radical radiotherapy for non-small cell lung cancer.
The lung volume receiving a dose of 10 Gy was the most important dosimetric
factor which influenced the post-radiation acute pneumonitis.
Key words: NSCLC, conformal radiotherapy, post-radiation pneumonitis. 
Introduction
The goal of radiotherapy is to cure cancer locally without excessive
toxicity. The optimal way to achieve this goal is to precisely deliver an
irradiation dose to the target volume, and no or a minimal dose to the
uninvolved normal tissues and structures (organs at risk). Numerous
studies suggest that higher irradiation dose results in better disease-free
survival. In many tumours, such as carcinoma of the uterine cervix,
prostate, and lung cancer, higher local control is correlated with increased
survival. 
Complete surgical resection is the most effective initial treatment for
patients with early stage non-small cell lung cancer (NSCLC). Local relapses
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in the tumour bed and regional lymph nodes or
distant metastases are the mechanism of relapse
after curative resection [1, 2]. Radiation therapy is
the primary treatment for NSCLC, either as adjuvant
treatment after surgery or as radical treatment in
patients with locoregional advanced, inoperable
tumour. It was reported that high radiation doses
were correlated with improvement of local control
[3-5]. Radiation-induced pulmonary injury is one of
the most common and serious complications in
patients who receive high-dose radiation therapy
for non-small cell lung cancer. The use of three-
dimensional conformal radiotherapy allows for
improved target volume coverage as well as better
ability to spare normal lung tissue. Nevertheless,
the percentage of patients who experience post-
radiation pneumonitis fluctuates between 6% and
49% [6-20]. Several clinical factors as well as specific
dose-volume histogram (DVH) parameters have
been reported as risk factors for radiotherapy-
related lung injury in NSCLC patients. Poor
performance status, concurrent smoking, age, 
low haemoglobin concentration, concurrent chemo  -
therapy, history of chronic obstructive pulmonary
disease (COPD), and poor pulmonary function
before radiotherapy have been reported as common
clinical factors related to post-radiation lung injury
[17, 21-24]. Many studies have reported that the
percentage volume of lung receiving more than
some defined threshold dose and mean lung dose
(MLD) are predictive factors for post-radiation acute
lung toxicity. Most reported results in the literature
are inconsistent. In this study we tried to express
our opinion in the discussion. We herein report our
study results of radiation-induced lung toxicity in
a group of 34 patients with NSCLC, treated using
three-dimensional conformal techniques. The aim
of this study was to evaluate the risk of acute side
effects in the lung after 3D-CRT in patients treated
for NSCLC. An attempt was made to single out
clinical factors and factors related to treatment
technique which may induce acute post-radiation
pneumonitis.
Material and methods 
From September 2004 to March 2006, 
34 consecutive patients were enrolled in
a prospective study to evaluate pulmonary toxicity
following 3D-CRT. They were treated in the
Radiotherapy Department, Chair of Oncology of
Medical University of Lodz. There were 25 males
and 9 females in this group. The male : female 
ratio was 2.7 : 1. Patient’s age was in the range 
48-81 years (mean 63.4 years; standard deviation
[SD] 8.4; median 63.0 years; 95% confidence interval
[95% CI] 60.7-66.0). The clinical stage evaluation,
and qualification of patients for radiation therapy
were established after conducting medical
examination, chest x-ray film in antero-posterior
and lateral projection, chest computed tomography
study, abdominal ultrasonography and bron  -
choscopy. The tumour size (the largest diameter
defined in millimetres, measured in the chest
computed tomography study) was in the range 
20-85 mm (mean 45.3 ±18 mm; median 40.0 mm;
95% CI 39.7-50.8). In most cases, patients who were
qualified for radical radiotherapy were in clinical
stage III: frequency of stage IIIa and IIIb was 41%
and 29% respectively. Seven patients (5 in clinical
stage II and 2 in clinical stage I lung cancer) were
disqualified from surgery because of other
coexisting medical contraindications. Three patients
in the analysed group (1 in clinical stage II and 2 in
clinical stage I) did not consent to surgery. Clinical
stage distribution according to TNM classification
is presented in Table I.
The haemoglobin concentration before treat  -
ment fluctuated between 10.3 g/dl and 15.9 g/dl
(mean 13.3 ±1.51 g/dl; median 13.3 g/dl; 95% CI 12.5-
13.7). In the analysed group, patients’ performance
status was evaluated using the Karnofsky
Performance Scale (KPS). All patients were in very
good or good general condition. There were 4 (12%)
patients with 100% KPS. Sixteen (47%) and 14 (41%)
patients were classified respectively as 90% and
80% KPS. Twenty-five (73.6%) patients underwent
chemotherapy with a platinum-based regimen
before radiation therapy. Twenty-one (61.8%)
patients received cisplatin in a dose of 100 mg/m2
with etoposide 100-120 mg/m2 every 21 days. Four
(11.8%) patients received cisplatin in monotherapy.
The number of chemotherapy courses ranged
between 2 and 5 (median 3.8 courses). In every case
the diagnosis of non-small cell lung cancer was
confirmed in histopathology examination. In the
analysed group squamous cell carcinoma was
diagnosed in 21 (61.8%) patients. Adenocarcinoma
was recognized in 5 (14.7%) patients. The same
T/N N0 N1 N2 N3 No. of 
patients
T1 01 203
0.00% 2.94% 5.88% 0.00% 8.82%
T2 44 61 1 5
11.76% 11.76% 17.65% 2.94% 44.12%
T3 10 6 07
2.94% 0.00% 17.65% 0.00% 20.59%
T4 22 329
5.88% 5.88% 8.82% 5.88% 26.47%
No. of  7 7 17 3 34
patients
20.59% 20.59% 50.00% 8.82% 100.00%
Table I. Clinical stage according to TNM classification
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number of patients had diagnosis of large cell
carcinoma. In the remaining 3 (8.8%) patients the
precise pathological diagnosis was not established.
In these cases non-small cell lung cancer was
recognized. 
Treatment technique
All patients were treated according to the
Radiotherapy Department’s homogeneous in-house
protocol. Patients were positioned and fixed using
a breast board with arms abducted over the head.
Preliminary treatment volume localization was done
using a simulator. The planning CT scans were sent
to the Medical Physics Department, where
treatment volumes as well as critical organs and
radiation dose were defined using the Varian Eclipse
treatment planning system. Every case was planned
individually using three-dimensional conformal
technique. Treatment volumes were defined
according to the 50 and 62 ICRU (the International
Commission on Radiation Units and Measurements)
reports. The gross tumour volume (GTV) was
delineated as the tumour with enlarged mediastinal
lymph nodes (lymph nodes larger than 1 cm in
computed tomography study). Next the clinical
target volume (CTV) was defined as a volume which
included the GTV and some subclinical disease. The
CTV was usually created by adding a symmetrical
margin of 5 mm to the GTV. Then an additional
tissue margin around the CTV was created to
eliminate the respiratory motion effect and
potential inaccuracy of patient and radiation 
source setup. By adding these margins the planning
target volume (PTV) was created. Margins around
the CTV, in the range 1.0-1.5 cm, usually were
asymmetrical, and were dependent on respiratory
motion and tumour site. Correctness of treatment
plan realization was checked on a simulator, 
where treatment fields were transmitted to the
patient’s skin, and served in the computer 
system simultaneously. Treatment fields setup
repeatability was evaluated through the simulator
and accelerator image fusion and geometric error
measurement. Twenty-one (64.8%) patients had
ipsilateral mediastinal lymph nodes irradiated
electively. For precise delineation of individual
mediastinal lymph node groups, Mountain and
Dresler’s classification modified by Chapet was
used. The radiation dose in the elective volume
was prescribed at a level of 50.0 Gy. Next the dose
was escalated to the tumour and enlarged
mediastinal lymph nodes, and it was contained
within 66.0-68 Gy. For 11 (32.3%) patients the “large
field” technique was used, which included tumour
and ipsilateral mediastinal lymph nodes. The total
dose between 66.0 Gy and 68.0 Gy was prescribed
in this group of patients. One patient was treated
using the “small field” technique, limited to the
tumour volume and pulmonary hilum lymph nodes.
The prescribed dose was 66.0 Gy for this patient.
All patients were irradiated using a conventional
dosage schedule. 
The basis of statistical analysis was occurrence
of acute post-radiation pneumonitis in this group
of patients. Intensity of early toxicity was evaluated
once a week during radiotherapy, and then every 
4 weeks, for six months after the end of treatment.
A modified RTOG/EORTC toxicity score was used.
The toxicity score modification involved changing
the corticosteroid administration from grade 3 to
grade 2 on the above-mentioned scale. The
introduced change allowed us to single out a group
of patients with indirect degree of post-radiation
acute reaction course. Corticosteroid administration
induced relatively rapid amelioration of respiratory
system functioning in this group of patients,
without the necessity of hospitalization. In the
presented statistical analysis the main endpoint
was the occurrence of radiation pneumonitis of
grade 2 or higher according to the modified
RTOG/EORTC toxicity score, with clinical
manifestation of moderate effort dyspnoea with
non-productive persistent cough, subfebrile body
temperature and necessity of corticosteroid
administration. In case of any uncertainty of
pathogenesis of a patient’s ailments, which could
suggest local recurrence or tumour progression,
computed tomography of the chest was performed
as well as cardiological consultation to eliminate
other causes of respiratory failure.
Statistical analysis
The Kaplan-Meier estimator was used to
evaluate the risk of radiation pneumonitis
development in the analysed patient group.
Student’s t-test, as a statistical method, was used
to define differences between mean values of
target volumes, mean doses cumulated in lung
tissue as well as lung volumes receiving specified
ionizing radiation doses, in groups of patients with
and without clinical manifestation of post-radiation
pneumonitis. Patient-related factors included in the
analysis were: age, sex, tumour size, clinical stage,
Karnofsky Performance Status, use of induction
chemotherapy, and haemoglobin concentration
before radiotherapy. Factors related to treatment
techniques included in the analysis were: clinical
target volumes and planning target volumes in cm3,
volumes of lung tissue which received a dose from
10 Gy to 60 Gy, and mean lung doses. Finally,
univariate and multivariate analysis was carried out,
to single out factors which could describe the
toxicity risk most precisely. Lung tissue, as an organ
at risk, was defined separately in every case as: the
ipsilateral lung, contralateral lung, and total lung
volume. A p value < 0.05 was considered significant. 
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Results 
Fifty-three percent of patients included in 
the study suffered from acute post-radiation
pneumonitis. Fifteen (44.1%) patients experienced
grade 2, and 3 (8.9%) patients grade 3 toxicity
according to the modified RTOG/EORTC scale. No
grade 4 toxicity was recorded in this study. All
patients with grade 3 lung toxicity required
hospitalization and intensive medical care. The
mean time to clinical manifestation of acute post-
radiation reaction in patients who experienced post-
radiation pneumonitis was 5.3 weeks (min 2.7 weeks;
max 16 weeks, median 7.4; 95% CI 4.2-8.7 weeks).
In all patients except 2, acute post-radiation
pneumonitis revealed itself before the end of the
third month after the end of radiotherapy. In these
2 patients the acute post-radiation pneumonitis
occurred at weeks 13 and 16 after the end of
treatment. 
The mean volumes of lung tissue which received
doses in the range of 10-60 Gy in the analysed
group are presented in Figure 1. A-C. 
Clinical factors including age, sex, tumour size,
clinical stage, Karnofsky Performance Status, use
of induction chemotherapy, and haemoglobin
concentration before radiotherapy did not have any
impact on acute lung toxicity risk (p ≥ 0.18). 
The analysis of dose-volume histograms showed
a difference in lung volumes receiving low doses
(10 Gy, 20 Gy) in groups of patients with and
without clinical manifestation of the side effect 
(p ≤ 0.01). The mean ipsilateral lung volume
receiving 10 Gy in patients with post-radiation
pneumonitis was 70.37%, and only 57.22% in
patients without clinical manifestation of this acute
side effect (p = 0.002). Also differences of mean
contralateral and total lung volume, in both groups
of patients, with and without clinical manifestation
of post-radiation pneumonitis, were statistically
significant, at a dose level of 10 Gy. These
differences were 46.04% vs. 31.44% for contralateral
lung and 56.73% vs. 38.68% for total lung volume
respectively (p = 0.011; p < 0.001). Statistically
significant mean volume differences of ipsilateral
lung tissue, contralateral and total lung volume
were demonstrated for a 20 Gy dose as well.
Differences in both groups of patients with and
without clinical manifestation of post-radiation
pneumonitis were 58.16% vs. 47.66% for ipsilateral
lung (p = 0.007). For contralateral and total lung
volume these differences were respectively 17.91%
vs. 10.00% and 36.14% vs. 12.41% (p = 0.016; 
p < 0.001). For lung tissue receiving higher doses,
in the range of 30–60 Gy, statistically significant
differences were observed in total lung volume only.
For the dose of 30 Gy the difference was 25.23% vs.
14.59% (p < 0.001), and 19.28% vs. 11.36% for the
dose level of 40 Gy (p < 0.001). For the 50 Gy and
Figure 1. The relationship between lung tissue mean
volumes and absorbed doses in the range of 10-60 Gy.
A– ipsilateral lung; B– contralateral lung; C– total lung
volume
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60 Gy doses these differences, in mean total lung
volumes, were respectively 13.51% vs. 7.64% and
8.64% vs. 4.02% in the groups of patients with and
without clinical manifestation of post-radiation
pneumonitis (p = 0.001; p < 0.003). Results of this
analysis are presented in Table II. The analysis of
the mean dose in the lung tissue defined as
ipsilateral, contralateral and total lung volume
showed a statistically significant difference in the
case of total lung volume only. The mean dose
which was absorbed in the total lung volume in the
group of patients with post-radiation pneumonitis
was 21.23 Gy, compared with 15.86 Gy in the group
of patients without any signs of this acute side
effect (p = 0.008). Neither high dose volumes in the
ipsilateral lung, contralateral lung, mean ipsilateral
and contralateral lung doses, nor PTVs or CTVs
(cm3), showed a statistically significant difference
in this patient population (p ≥ 0.07).
The univariate analysis showed that the lung
volumes receiving a dose of 10 Gy, ipsilateral lung
and total lung volume receiving 20 Gy, and total
lung volume receiving doses of 30 Gy and 40 Gy
were correlated with the post-radiation pneumonitis
risk. The multivariate analysis showed that only
total lung volume receiving a dose of 10 Gy 
was correlated with the risk of post-radiation
pneumonitis (p = 0.01). Results of the univariate
and multivariate analysis are presented in 
Tables III and IV.
Discussion
The clinical manifestation of acute post-radiation
toxicity of the lung tissue is the most frequently
occurring side effect in patients with NSCLC after
radical radiotherapy, which limits the possibility to
deliver a high dose of ionizing radiation. The use of
3D-CRT with a growing number of therapeutic
beams orientated to the patient in varied angles
and positions causes better ability to spare normal
lung tissue, but a great deal of lung volume absorbs
low, scattered doses. In the present study we have
attempted to identify clinical and dosimetric factors
which can be responsible for clinical manifestation
of lung injury in patients after radical radiotherapy.
In the evaluated patient group acute post-radiation
pneumonitis grade 2 had clinical manifestation in
15 (44.1%) patients, and 3 (8.9%) patients
experienced grade 3 toxicity on the modified
RTOG/EORTC scale. No grade 4 was recorded. The
occurrence of grade 2 toxicity in this group of
patients was not a significant clinical problem. We
observed relatively rapid respiratory function
amelioration after corticosteroid administration in
these cases. Multiple reports based on RTOG/EORTC
toxicity scores have described the percentage of
grade 2 in the range of 7.8-36% [6, 10, 14, 15], and
grade 3 in 2-14.3% of cases [6, 10, 15]. Inoue et al.
reported toxicity of grade 1 and 2 in 36% of
patients. Grade 3 and 4 toxicity was reported in 13%
Post RT (+)  Post RT (–) t df p
V10 ipsilateral lung 70.37389 57.22625 3.447838 24 0.002
V10 contralateral lung  46.04722 31.44583 3.636192 28 0.001
V10 total lung 56.73556 38.68500 5.859693 28 < 0,001
V20 ipsilateral lung 58.16222 47.66000 2.913252 24 0.007
V20 contralateral lung 17.91167 10.99417 2.552560 28 0,016
V20 total lung 36.14778 20.41667 5.410399 28 < 0.001
V30 ipsilateral lung 45.67556 37.78500 1.870949 24 0.074
V30 contralateral lung 7.86222 6.64583 0.852244 28 0.401
V30 total lung 25.23111 14.59667 4.843179 28 < 0.001
V40 ipsilateral lung 35.66556 30.15125 1.428069 24 0.166
V40 contralateral lung 5.18278 4.90333 0.234055 28 0.816
V40 total lung 19.28056 11.36417 4.204558 28 < 0.001
V50 ipsilateral lung 25.66556 21.17125 1.206850 24 0.239
V50 contralateral lung 2.96278 2.97333 –0.013575 28 0.989
V50 total lung 13.51056 7.64083 3.623866 28 0.001
V60 ipsilateral lung 16.91389 12.22500 1.324020 24 0.198
V60 contralateral lung 1.45611 1.11083 0.733943 28 0.469
V60 total lung 8.64500 4.02000 3.276891 28 < 0.003
Post RT (+) – patients with clinical manifestation of post-radiation pneumonitis, Post RT (–) – patients without any signs of side effects 
Table II. Student’s t test results for mean volumes of lung tissue which received doses in the range of 10-60 Gy 
Michał Spych, Leszek Gottwald, Małgorzata Klonowicz, Michał Biegała, Robert Bibik, Jacek FijuthArch Med Sci 5, October / 2010 761
of patients in this study [6]. The group from St Louis
described the risk of acute toxicity manifestation
of grade 2 or higher in 14% of patients 6 months
after radiotherapy. There were reported 4 deaths
due to acute post-radiation pneumonitis [10]. Wang
et al. reported the risk of acute lung toxicity of grade
3 or higher at a level of 6.7%. About 4% of patients
died because of this complication after radiotherapy
in this study [14]. The group from the Memorial
Sloan Kettering Cancer Centre reported 18.3% of
patients with acute lung toxicity of grade 3 or
higher according to the RTOG/EORTC toxicity score.
The percentage of deaths due to lung toxicity was
4%, similarly as in the Wang et al. study [15]. In our
study the toxicity score modification consisted in
changing the corticosteroid administration from
grade 3 to grade 2 on the above-mentioned scale.
The introduced change allowed us to single out
a group of patients with indirect degree of post-
radiation acute reaction course. The lack of uniform
criteria for post-radiation pulmonary injury makes
it difficult to compare the incidence and severity of
post-radiation pneumonitis between published data.
In comparing published data it is important to take
into account that therapeutic indications for
corticosteroid administration may be different in
particular centres and departments. The results of
our study, if we refer to the percentage of patients
with clinical manifestation of grade 3 acute post-
radiation pneumonitis according to RTOG/EORTC,
are similar to published data from other centres 
[6, 10, 15]. 
A number of recently published reports evaluating
toxicity after radiotherapy in patients with NSCLC
are based on detailed analysis of dose-volume
histograms. The purpose of these studies was 
to detect factors that increased the risk of acute
post-radiation pneumonitis. Investigators have de  -
monstrated that the larger was the volume of lung
tissue receiving some defined radiation dose, the
higher was the risk of acute post-radiation lung
injury. Some investigators have reported a similar
relation to mean dose absorbed in the lung tissue.
In the presented statistical analysis clinical
manifestation of acute post-radiation pneumonitis
revealed itself most often in patients who received
low doses in a large volume of lung tissue, which
was defined as ipsilateral, contralateral and total
lung volume. The multivariate analysis conducted in
the present study showed a strong relation between
total lung volume receiving a dose of 10 Gy and the
risk of acute lung injury. For lung volumes which
received higher doses, in the range of 30-60 Gy,
statistically significant differences were observed in
total lung volume only. 
Similar results were reported by Graham et al. In
their study the dose of 20 Gy and the mean dose
in total lung volume were the factors of the risk of
Factors related to treatment technique P
V10 ipsilateral lung > 63% 50% 0.005
< 63% 50%
V10 contralateral lung > 40% 44% 0.01
< 40% 56%
V10 total lung > 48% 54% < 0.001
< 48% 46%
V20 ipsilateral lung > 52% 64% 0.007
< 52% 36%
V20 contralateral lung > 15% 49% 0.090
< 15% 51%
V20 total lung > 28% 56% < 0.001
< 28% 44%
V30 ipsilateral lung > 39% 73% 0.057
< 39% 27%
V30 contralateral lung > 7% 33% 0.618
< 7% 67%
V30 total lung > 18% 69% < 0.002
< 18% 31%
V40 ipsilateral lung > 30% 61% 0.229
< 30% 39%
V40 contralateral lung > 5% 36% 0.998
< 5% 64%
V40 total lung > 14% 64% 0.005
<14% 36%
V50 ipsilateral lung  >21% 64% 0.148
<21% 36%
V50 contralateral lung > 3% 38% 0.830
< 3% 62%
V50 total lung > 10% 56% 0.062
< 10% 44%
V60 ipsilateral lung > 13% 45% 0.169
< 13% 55%
V60 contralateral lung > 1.3% 31% 0.658
< 1.3% 69%
V60 total lung > 6% 46% 0.05
< 6% 54%
Mean dose  > 32 Gy 61% 0.061
in ipsilateral lung < 32 Gy 39%
Mean dose  > 12 Gy 46% 0.220
in contralateral lung < 12 Gy 54%
Mean dose  > 18 Gy 59% 0.063
in total lung volume < 18 Gy 41%
Table III. Univariate analysis results of prognostic
factors related to treatment technique
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Beta – coefficient, SD – standard deviation, HR – hazard ratio, W – Wald statistic 
Beta SD HR W p
V10 ipsilateral lung 0.16870 1.182774 1.183765 0.020344 0.887
V10 contralateral lung 0.65372 0.654240 1.922673 0.998401 0.318
V10 total lung  –3.03132 1.208014 1.448252 6.296779 0.012
V20 ipsilateral lung –0.97686 1.308891 0.376491 0.557003 0.455
V20 total lung –0.02526 0.937207 0.975052 0.100727 0.978
V30 total lung 1.01562 1.702373 2.761082 0.355923 0.551
V40 total lung –0.68254 0.919531 0.505331 0.550967 0.458
Table IV. Multivariate analysis results
post-radiation lung toxicity. In univariate analysis
the p values for these variables were 0.001 and 0.01
respectively. The multivariate analysis demonstrated
that the lung volume which received the low dose
of 20 Gy was the only prognostic factor for
evaluation of the risk of acute post-radiation
pneumonitis (p = 0.001). Additionally, the authors
reported a direct statistical correlation between lung
volume which received a dose of 20 Gy and acute
lung toxicity intensification. There were no reported
cases of acute post-radiation pneumonitis in the
group of patients which received a dose of 20 Gy
in less than 22% of total lung volume. For the range
22-31% of total lung volume which received the
above-specified dose, the authors reported acute
post-radiation pneumonitis of grade 2 according to
the RTOG/EORTC toxicity score in 8% of patients.
In the group of patients which received a dose of
20 Gy in total lung volume larger than 40%, 
the risk of serious incidents of acute post-radiation
pneumonitis (grade 3-5 according to the
RTOG/EORTC toxicity score) was 8%. Three patients
died due to acute lung toxicity in this group of
patients [10]. Similar results were reported by
a group from Mayo Clinic. The authors reported
a statistically significant relation between clinical
manifestation of grade 2 acute post-radiation
pneumonitis and the mean dose in the total lung
volume. A statistically significant relation between
total lung volume which received a dose equal to
or higher than 10, 13, 15, 20 and 30 Gy, and grade
2 lung toxicity was reported in this study as well
[8]. The group from M.D. Anderson Cancer Centre
confirmed a thesis on particular sensitivity of lung
tissue to low total and fractional doses of ionizing
radiation. The range of low radiation doses
absorbed in a large volume of lung tissue in
patients treated for NSCLC, as well as mean dose
in lung tissue, had an impact on clinical
manifestation of post-radiation pneumonitis.
Patients who received a dose of 5 Gy in total lung
volume smaller than 42% had a lower risk of post-
radiation lung toxicity compared to patients who
received the same dose in a lung volume larger
than 42% (p = 0.001) [12].
In the present study a statistical correlation
between percentage total lung volume which
received higher doses (40, 50 and 60 Gy) and the
risk of clinical manifestation of post-radiation
pneumonitis was demonstrated. This kind of
correlation was not reported by authors from
Washington University Medical Centre and Mayo
Clinic [8]. This may result from differences in the
definition of percentage total lung volume. The
authors of those studies created total lung volume
in the computer planning system excluding three
volumes: GTV, CTV and PTV. In the present study
ipsilateral and total lung volume were reduced by
exclusion of CTV and PTV, but not GTV. Exclusion of
these three volumes from the total lung volume
could have a relatively large impact on the high
dose distribution in lung tissue. 
The presented results as well as published data
indicate that the risk of lung toxicity clinical
manifestation is the most important factor which
limits our ability to safely deliver a planned dose of
ionizing radiation inside the thorax. In the course
of treatment planning it is very important to pay
special attention to low dose distribution in lung
volume. Such a disadvantageous low dose
distribution in lung tissue may result from using
a large number of oblique therapeutic beams, which
permit the delivery of nearly 100% of the planned
dose to the PTV, but on the other hand significant
lung tissue volume absorbs a low, dispersed dose
of ionizing radiation. New treatment techniques of
radiotherapy in patients with NSCLC are being
evaluated to spare lung tissue and other organs
and to reduce the toxicity risk [25, 26]. Additional
studies are needed for a more robust description of
the dose-volume effect following thoracic irradiation
in lung cancer patients.
In conclusions, in this analysis, the lung volume
receiving a dose of 10 Gy is the most important
dosimetric factor which influenced the post-
radiation acute pneumonitis. Clinical manifestation
of acute post-radiation pneumonitis revealed itself
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most often in patients who received low doses in
a large volume of lung tissue.
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